Clinical Trials Logo

Glucocorticoids clinical trials

View clinical trials related to Glucocorticoids.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05598424 Recruiting - Clinical trials for Chronic Rhinosinusitis With Nasal Polyps

CST1 Predictive Model of Oral Glucocorticoid Therapy Sensitivity for Chronic Rhinosinusitis With Polyps

Start date: November 22, 2022
Phase: Phase 4
Study type: Interventional

Topical and systemic steroids constitute the first choice in medical treatment for nasal polyps. Glucocorticoids sensitivity is significantly correlated with CST1 level in nasal secretions. The goal of this single-arm clinical trial based on a multicenter platform is to test CST1 in patients with chronic rhinosinusitis and nasal polyps before and after oral glucocorticoid therapy. Endoscopic polyp score, Total Nasal Symptom Score(TNSS), SNOT-22 score and other biomarkers are also evaluated before and after the treatment. Researchers will develop a CST1 predictive model of oral glucocorticoid therapy for Chronic Rhinosinusitis with Polyps.

NCT ID: NCT05522465 Recruiting - Clinical trials for Immune Thrombocytopenia

Short-course High-dose Prednisone and Dexamethasone in Children With ITP

Start date: October 11, 2022
Phase: Phase 4
Study type: Interventional

Comparison of the efficacy and safety of short-course high-dose prednisone and dexamethasone in the treatment of children with newly diagnosed immune thrombocytopenia (ITP)

NCT ID: NCT04574232 Recruiting - Glucocorticoids Clinical Trials

SporTRIA Study: A Multicentre Trial for Excretion Kinetics of Triamcinolone Acetonide Following Sport Related Intra-articular Injections in Knees; Definitions of the Washout Periods

SporTRIA
Start date: January 1, 2023
Phase: N/A
Study type: Interventional

Intra-articular and peri-articular glucocorticoid (GC) injections are common in sports medicine. However, from 1st January 2022, all injectable GC routes (including intra-articular administration (IA)) will be prohibited in-competition by World Anti-Doping Agency (WADA). Due to these rules, an IA GC treatment out-of-competition could result in an adverse analytical finding (AAF) in-competition if the washout period is not clearly defined. The aim of this study is to determine the urinary excretion profile of triamcinolone acetonide following IA to help in the definition of the washout periods.

NCT ID: NCT04094298 Recruiting - Rotator Cuff Tears Clinical Trials

Use of Extended Release Triamcinolone in the Treatment of Rotator Cuff Disease

Start date: July 15, 2019
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to assess the overall safety and general tolerability of extended release triamcinolone acetate (TA-ER/FX006) in patient with rotator cuff disease. The study will enroll 65 patients, aged 40-75 years old, in a longitudinal case series level IV study using extended release triamcinolone to treat shoulder pain from rotator cuff disease. Inclusion criteria will be shoulder pain without a history of trauma and physical exam consistent with rotator cuff tendinitis, impingement syndrome or rotator cuff tear.